Bundang Cha Hospital Introduces Korea's First Targeted Radioactive Ligand Treatment 'Pluvicto'
Aug 28, 2024
Cha Medical University Bundang Cha Hospital (Director Yoon Sang-wook) announced that for the first time in Korea, it has introduced a radioactive ligand treatment called pluvicto (Rutetium (177Lu) for prostate cancer and started treatment.
Fluvicto, approved by the U.S. Food and Drug Administration (FDA) in 2022, is a radioactive ligand treatment produced by the combination of the cytotoxic radioisotope rutetium (177Lu) and the target ligand PSMA-617. It is considered a next-generation innovative treatment that effectively kills cancer cells by delivering therapeutic radiation to cancer cells in combination with 'prostate-specific membrane antigen (PSMA)' that is highly expressed on the surface of prostate cancer cells.
Pluvicto is an applicable treatment for prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer (mCRPC) patients who previously received androgen receptor pathway block (ARPI) treatment and turbic acid-based chemotherapy. Metastatic castration-resistant prostate cancer is the most serious stage of prostate cancer, and it refers to a condition in which cancer spreads out of the prostate to surrounding organs, lymph nodes, bones, and lungs, and cancer cells are not suppressed even if male hormone levels are lowered.
For Pluvicto treatment, medical staff of hematologic oncology and urology check the suitability of treatment through medical consultation, and proceed with treatment according to the radioactive drug reservation procedure. On the day of treatment, the nuclear medicine department administers fluvicto intravenously without any special pretreatment and does not require isolation, so patients can return home immediately on the day. It is important to ensure that adequate organ and bone marrow function is maintained through blood tests before and during fluvicto administration. Every Tuesday and Thursday at Bundang Cha Hospital, fluvicto treatment is performed.
Fluvicto treatment was found to extend survival by two times in the PSMA-positive metastatic castration-resistant prostate cancer patient group compared to when standard treatment alone was performed. In addition, in a clinical study of 831 patients with PSMA-positive metastatic castration-resistant prostate cancer, the standard treatment combination therapy group with pluvicto had a radiological progression-free survival (rPFS) of 8.7 months, longer than the standard treatment alone group's 3.4 months. Fluvicto and standard treatment combination therapy reduced the risk of disease progression or death by 60%, and even in the overall survival (OS), the fluvicto and standard treatment combination therapy group was 15.3 months, significantly reducing the risk of death by 38% compared to 11.3 months in the standard treatment alone group.
Professor Moon Yong-hwa of the Department of Hematologic Oncology at Bundang Cha Hospital said "The introduction of this treatment is expected to provide new hope for patients with metastatic castration-resistant prostate cancer without treatment alternatives." he said.
Fluvicto, approved by the U.S. Food and Drug Administration (FDA) in 2022, is a radioactive ligand treatment produced by the combination of the cytotoxic radioisotope rutetium (177Lu) and the target ligand PSMA-617. It is considered a next-generation innovative treatment that effectively kills cancer cells by delivering therapeutic radiation to cancer cells in combination with 'prostate-specific membrane antigen (PSMA)' that is highly expressed on the surface of prostate cancer cells.
Pluvicto is an applicable treatment for prostate-specific membrane antigen (PSMA)-positive metastatic castration resistant prostate cancer (mCRPC) patients who previously received androgen receptor pathway block (ARPI) treatment and turbic acid-based chemotherapy. Metastatic castration-resistant prostate cancer is the most serious stage of prostate cancer, and it refers to a condition in which cancer spreads out of the prostate to surrounding organs, lymph nodes, bones, and lungs, and cancer cells are not suppressed even if male hormone levels are lowered.
For Pluvicto treatment, medical staff of hematologic oncology and urology check the suitability of treatment through medical consultation, and proceed with treatment according to the radioactive drug reservation procedure. On the day of treatment, the nuclear medicine department administers fluvicto intravenously without any special pretreatment and does not require isolation, so patients can return home immediately on the day. It is important to ensure that adequate organ and bone marrow function is maintained through blood tests before and during fluvicto administration. Every Tuesday and Thursday at Bundang Cha Hospital, fluvicto treatment is performed.
Fluvicto treatment was found to extend survival by two times in the PSMA-positive metastatic castration-resistant prostate cancer patient group compared to when standard treatment alone was performed. In addition, in a clinical study of 831 patients with PSMA-positive metastatic castration-resistant prostate cancer, the standard treatment combination therapy group with pluvicto had a radiological progression-free survival (rPFS) of 8.7 months, longer than the standard treatment alone group's 3.4 months. Fluvicto and standard treatment combination therapy reduced the risk of disease progression or death by 60%, and even in the overall survival (OS), the fluvicto and standard treatment combination therapy group was 15.3 months, significantly reducing the risk of death by 38% compared to 11.3 months in the standard treatment alone group.
Professor Moon Yong-hwa of the Department of Hematologic Oncology at Bundang Cha Hospital said "The introduction of this treatment is expected to provide new hope for patients with metastatic castration-resistant prostate cancer without treatment alternatives." he said.
|
bellho@sportschosun.com
